ClinicalTrials.Veeva

Find clinical trials for Prostate Cancer in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Recurrence
Adenocarcinoma
Castration-Resistant Prostatic Cancer

Prostate Cancer trials near Budapest, Budapest, HUN:

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280)

plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the doce...

Enrolling
Prostate Cancer
Drug: docetaxel
Drug: capivasertib

Phase 3

AstraZeneca
AstraZeneca

Budapest, Hungary and 249 other locations

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

Phase 3

Aragon Pharmaceuticals

Budapest, Hungary and 388 other locations

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate...

Active, not recruiting
Metastatic Prostate Cancer
Drug: Ipatasertib
Drug: Placebo

Phase 3

Roche
Roche

Budapest, Hungary and 183 other locations

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with on ...

Active, not recruiting
Metastatic Prostate Cancer
Prostate Adenocarcinoma
Drug: Cabozantinib
Drug: Abiraterone Acetate

Phase 3

Exelixis
Exelixis

Budapest, Hungary and 272 other locations

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means tha ...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

Phase 3

Bayer
Bayer

Budapest, Hungary and 258 other locations

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA...

Enrolling
Metastatic Castration-Sensitive Prostate Cancer
Drug: Abiraterone Acetate
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Budapest, Hungary and 394 other locations

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer...

Active, not recruiting
Prostatic Neoplasms
Cytochrome P-450
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

Phase 3

Lilly
Lilly

Budapest, Pest, Hungary and 259 other locations

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

Phase 3

Pfizer
Pfizer

Budapest, Hungary and 313 other locations

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-gener...

Enrolling
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms
Drug: Enzalutamide
Drug: Hydrocortisone

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Budapest, Pest, Hungary and 85 other locations

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN)

The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free...

Active, not recruiting
Prostate Cancer
Drug: Androgen Deprivation Therapy (ADT)
Drug: Placebo

Phase 3

Aragon Pharmaceuticals

Budapest, Hungary and 228 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems